Wilms tumor 6

disease
On this page

Also known as Wilms tumor 6WT6Wilms tumor type 6Wilms tumour 6, susceptibility toWilms tumour 6Wilms tumour type 6

Summary

Wilms tumor 6 (MONDO:0014779) is a cancer caused by REST (GenCC Strong), with 1 cohort gene (1 CIViC-evidence somatic driver; 58 ClinVar predisposition records).

At a glance

  • Classification: Cancer
  • Causal gene: REST (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 58

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical nameWilms tumor 6
Mondo IDMONDO:0014779
OMIM616806
UMLSC3891301
MedGen855962
GARD0016162
Is cancer (heuristic)yes

Also known as: Wilms tumor 6 · Wilms tumor 6; WT6 · Wilms tumor type 6 · Wilms tumour 6, susceptibility to · Wilms tumour 6; WT6 · Wilms tumour type 6 · WT6

Data availability: 58 ClinVar variants · 4 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by etiologic mechanism › disease of genetic or genomic mechanism › hereditary diseasehereditary Wilms tumorWilms tumor 6

Related subtypes (6): Wilms tumor 1, Wilms tumor 2, Wilms tumor 3, Wilms tumor 4, Wilms tumor 5, Wilms tumor 7

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

58 retrieved; paginated sample, class counts are floors:

49 uncertain significance, 5 conflicting classifications of pathogenicity, 2 risk factor, 1 benign/likely benign, 1 pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
222002NM_005612.5(REST):c.831_832del (p.Cys278fs)RESTPathogeniccriteria provided, single submitter
222003NM_005612.5(REST):c.773_776del (p.Val258fs)RESTrisk factorno assertion criteria provided
222004NM_005612.5(REST):c.965A>G (p.His322Arg)RESTrisk factorno assertion criteria provided
1019336NM_005612.5(REST):c.843C>T (p.Cys281=)RESTConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1135056NM_005612.5(REST):c.1902G>A (p.Met634Ile)RESTConflicting classifications of pathogenicitycriteria provided, conflicting classifications
2631848NM_005612.5(REST):c.2945G>A (p.Arg982His)RESTConflicting classifications of pathogenicitycriteria provided, conflicting classifications
3590636NM_005612.5(REST):c.458G>A (p.Ser153Asn)RESTConflicting classifications of pathogenicitycriteria provided, conflicting classifications
944664NM_005612.5(REST):c.3098A>G (p.His1033Arg)RESTConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1000502NM_005612.5(REST):c.2992G>A (p.Ala998Thr)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1013675NM_005612.5(REST):c.1747A>G (p.Thr583Ala)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1021123NM_005612.5(REST):c.2065C>T (p.Pro689Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1025535NM_005612.5(REST):c.1639G>T (p.Val547Leu)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1047303NM_005612.5(REST):c.2068C>T (p.Pro690Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1327569NM_005612.5(REST):c.2989A>G (p.Met997Val)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1347535NM_005612.5(REST):c.2050C>G (p.His684Asp)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1352070NM_005612.5(REST):c.2307A>G (p.Ile769Met)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1357352NM_005612.5(REST):c.2917A>G (p.Met973Val)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1418725NM_005612.5(REST):c.416A>G (p.Asp139Gly)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1446534NM_005612.5(REST):c.2780A>G (p.Asn927Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1524176NM_005612.5(REST):c.2032G>T (p.Ala678Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
1691514NM_005612.5(REST):c.1881G>T (p.Gln627His)RESTUncertain significancecriteria provided, single submitter
1931844NM_005612.5(REST):c.2753A>G (p.His918Arg)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2170568NM_005612.5(REST):c.2741A>G (p.Asn914Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2174361NM_005612.5(REST):c.608C>G (p.Ser203Cys)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2178538NM_005612.5(REST):c.3239A>G (p.Asn1080Ser)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2181622NM_005612.5(REST):c.2053A>G (p.Met685Val)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2444866NM_005612.5(REST):c.1882G>A (p.Val628Met)RESTUncertain significancecriteria provided, single submitter
2444874NM_005612.5(REST):c.1701G>C (p.Glu567Asp)RESTUncertain significancecriteria provided, single submitter
2444899NM_005612.5(REST):c.1583A>G (p.His528Arg)RESTUncertain significancecriteria provided, multiple submitters, no conflicts
2444901NM_005612.5(REST):c.1367A>G (p.Asp456Gly)RESTUncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 10 · Orphanet: 2 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Somatic driver evidence (intOGen + CIViC, cohort fanout)

GeneintOGen roleCancer typesCIViC
RESTLoFWT

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
RESTStrongAutosomal dominantWilms tumor 610

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RESTOrphanet:2024Hereditary gingival fibromatosis
RESTOrphanet:654Nephroblastoma

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RESTHGNC:9966ENSG00000084093Q13127RE1-silencing transcription factorgencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RESTRE1-silencing transcription factorTranscriptional repressor which binds neuron-restrictive silencer element (NRSE) and represses neuronal gene transcription in non-neuronal cells.

Protein-family classification

Druggable: 0 · Difficult: 1 · Unknown: 0 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Transcription factor18.3×0.121

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RESTTranscription factornoZnf_C2H2_type, Znf_C2H2_sf, Zinc_finger/UBP_domain

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
male germ line stem cell (sensu Vertebrata) in testis1
mucosa of paranasal sinus1
primordial germ cell in gonad1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
REST281ubiquitousmarkerprimordial germ cell in gonad, mucosa of paranasal sinus, male germ line stem cell (sensu Vertebrata) in testis

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
REST2,499

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
RESTQ131273

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 5. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Regulation of NPAS4 gene transcription12284.0×0.002REST
NGF-stimulated transcription1285.5×0.009REST
Regulation of PTEN gene transcription1178.4×0.009REST
HDACs deacetylate histones1120.2×0.009REST
Potential therapeutics for SARS1114.2×0.009REST

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
negative regulation of dense core granule biogenesis116852.0×0.001REST
negative regulation of amniotic stem cell differentiation116852.0×0.001REST
modification of synaptic structure18426.0×0.001REST
negative regulation of mesenchymal stem cell differentiation18426.0×0.001REST
negative regulation of aldosterone biosynthetic process14213.0×0.002REST
negative regulation of cortisol biosynthetic process14213.0×0.002REST
negative regulation of calcium ion-dependent exocytosis11872.4×0.003REST
cardiac muscle cell myoblast differentiation11404.3×0.003REST
host-mediated suppression of viral transcription11296.3×0.003REST
regulation of osteoblast differentiation11296.3×0.003REST
cellular response to electrical stimulus11296.3×0.003REST
nervous system process11203.7×0.003REST
positive regulation of programmed cell death11123.5×0.003REST
detection of mechanical stimulus involved in sensory perception of sound1936.2×0.003REST
cellular response to stress1842.6×0.003REST
auditory receptor cell stereocilium organization1842.6×0.003REST
neuronal stem cell population maintenance1674.1×0.003REST
negative regulation of neurogenesis1624.1×0.003REST
cellular response to glucocorticoid stimulus1624.1×0.003REST
negative regulation of miRNA transcription1624.1×0.003REST
negative regulation of insulin secretion1495.6×0.004REST
positive regulation of stem cell population maintenance1343.9×0.005REST
neuromuscular process controlling balance1330.4×0.005REST
negative regulation of neuron differentiation1271.8×0.006REST
response to ischemia1251.5×0.006REST
somatic stem cell population maintenance1247.8×0.006REST
regulation of alternative mRNA splicing, via spliceosome1244.2×0.006REST
hematopoietic progenitor cell differentiation1237.3×0.006REST
positive regulation of neuron differentiation1198.3×0.007REST
response to hypoxia195.8×0.013REST

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
REST00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Drug repurposing candidates

0 approved/phased drugs hit cohort targets but don’t yet appear in disease-level clinical trials. Target-inhibition rationale is strongest for cancer driver genes; a bioactivity hit is a screening signal, not a treatment claim.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1REST

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
REST0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.